Semaglutide achieves roughly 15 to 17 percent weight loss in phase 3 data
There is a loss of time for patient care and a huge increase in time burden outside the visit for doctors and pharmacists. Another major insurance change coming next year will affect another large swath of Dushays patients: In January, BCBS Massachusetts will be excluding all GLP-1s from coverage for treatment of obesity, reserving coverage for these drugs only when indicated to treat type 2 diabetes
The basic fact is that someone with a normal BMI has an almost 80% chance of reaching 70, with a BMI of 40-50 that chance is 50%[6]
However, blocking GLP-1R did not improve CM-related hypersensitivity
Some feel nauseous, tired, bloated, or uninterested in food
GLP-1 receptor agonists work by mimicking the action of endogenous GLP-1, an incretin hormone released from intestinal L-cells in response to food intake